Printer Friendly

NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD REVENUES AND PROFITS FOR THIRD QUARTER AND NINE MONTHS 1993

 Product Mix Shifts To Higher-Value-Added Health Care Products
 MIAMI, Oct. 21, /PRNewswire/ -- North American Biologicals, Inc. (NABI) (NASDAQ: NBIO) today reported record sales and net income for its third quarter ended Sept. 30, 1993. Sales reached $27.6 million, a 26 percent increase over sales of $21.9 million for the comparable quarter last year. Net income for the quarter was $988,000 or 7 cents per share compared with a net loss of $1 million or 9 cents per share in the comparable quarter last year.
 For the nine months ended Sept. 30, 1993, the Company reported sales of $71.8 million, up 20 percent from $60 million in the comparable period last year. Net income was $2.2 million, or 16 cents per share, versus a net loss of $59,000 in the first nine months last year.
 "We are extremely gratified by the continued record-breaking performance of the company this year, which includes a strong profit contribution from H-BIG(R), our first immunotherapeutic product," said David J. Gury, NABI's chairman, president and chief executive officer. "Our portfolio of new immunotherapeutics includes one product in advanced clinical trials, and another two immune globulins scheduled to enter clinical trials in 1994. Underlying these innovations in therapeutics is the continued growth of NABI's plasma collection network, which gives us unparalleled access to the raw materials necessary for the production of high-value-added products," Gury added.
 NABI management attributed the strong financial performance during the quarter and year to date to three major factors: increased volume, especially in higher-value-added hyperimmune plasmas; improved pricing of source and hyperimmune plasma products; and profit contribution from H-BIG. In addition, third quarter 1993 results included the positive impact of sales of plasma inventory from its new plasma collection facility in Norman, Okla., following FDA licensure in June.
 Among the highlights of the third quarter was the start by NIH of a Phase III multi-center clinical trial of HIVIG(TM), NABI's experimental HIV immune globulin product. The purpose of the trial is to determine the ability of HIVIG to safely prevent the transmission of the AIDS-causing virus from HIV-positive mothers to unborn infants. NABI is supplying HIVIG to the National Heart, Lung, and Blood Institute for this trial.
 North American Biologicals, Inc. is one of the world's largest providers of human blood plasma elements to the health care industry and is dedicated to improving the quality of human life by providing plasma and plasma-based products for diagnosis or therapy of immune disorders.


NORTH AMERICAN BIOLOGICALS, INC. SELECTED CONSOLIDATED FINANCIAL DATA
 (Thousands, Except Per Share Amounts)
 (Unaudited)
 Three Months Ended Nine Months Ended
 Sept. 30, Sept. 30,
 1993 1992 1993 1992
 Sales $27,628 $21,897 $71,767 $59,953
 Inc.(loss) bef.
 provision for inc.
 taxes and cumulative
 effect of accounting
 change for inc. taxes 1,474 (1,405) 3,125 (82)
 (Provision) benefit for
 inc.taxes (486) 393 (1,064) 23
 Inc. (loss) bef.
 cumulative effect of
 accounting change for
 inc. taxes 988 (1,012) 2,061 (59)
 Cumulative effect of
 accounting change for
 inc. taxes --- --- 100 ---
 Net inc. (loss) $988 $(1,012) $2,161 $(59)
 Earns. (loss) per share:
 Inc. (loss) bef.
 cumulative effect of
 accounting change for
 inc. taxes $.07 $(.09) $.15 ---
 Cumulative effect of
 accounting change for
 inc. taxes --- --- .01 ---
 Net inc. (loss) $.07 $(.09) $.16 $---
 Weighted avg. no.
 of shares and common
 share equivalents 13,563 11,530 13,484 13,258
 -0- 10/21/93
 /CONTACT: David J. Gury, chairman, president and CEO and Alfred J. Fernandez, VP Finance, both of NABI, 305-625-5303; or Marcia A. Kean, exec. VP and Lucy Morrison, associate, both of Feinstein Partners Inc., 617-577-8110 for North American Biologicals, Inc./
 (NBIO)


CO: North American Biologicals, Inc. ST: Florida IN: MTC SU: ERN

CM-JL -- NE001 -- 4970 10/21/93 08:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 21, 1993
Words:634
Previous Article:DOLLAR RENT A CAR TAKES ON LEADER'S ROLE IN 'VALUE' CATEGORY: 'RIGHT ON RATES' AVAILABLE THROUGH NOV. 22
Next Article:INTERNATIONAL CABLETEL INCORPORATED AND SWALEC SIGN AGREEMENT TO FORM JOINT VENTURE TO PROVIDE CABLE AND TELEPHONE SERVICE IN SOUTH WALES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters